This Article Full Text Full Text (PDF) Online Supplement All Versions of this Article: 200308-1104OCv1 169/7/822    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Griese, M. Articles by Scheuch, G. Search for Related Content PubMed PubMed Citation Articles by Griese, M. Articles by Scheuch, G.

Improvement of Alveolar Glutathione and Lung Function but Not Oxidative State in Cystic Fibrosis

Department of Pediatrics, Ludwig Maximilians University, Munich; Department of Nutrition, University of Hohenheim, Hohenheim; Department of Pediatrics, University of Cologne, Cologne; Inamed, Gauting; Department of Internal Medicine, Ludwig Maximilians University, Munich; Department of Pediatrics, University of Essen, Essen; and Institute for Inhalation Biology, GSF-Research Center for Environment and Health, Neuherberg, Germany

Correspondence and requests for reprints should be addressed to Matthias Griese, M.D., Dr. von Haunersches Kinderspital, Ludwig-Maximilians-University, Lindwurmstrasse 4, D-80337 Munich, Germany. E-mail: matthias.griese{at}med.uni-muenchen.de

Chronic neutrophilic inflammation leads to oxidative damage, which may play an important role in the pathogenesis of cystic fibrosis lung disease. Bronchoalveolar lavage levels of the antioxidant glutathione are diminished in patients with cystic fibrosis. Here we evaluated the effects of glutathione aerosol on lower airway glutathione levels, lung function, and oxidative status. Pulmonary deposition of a radiolabeled monodisperse aerosol generated with a Pari LC Star nebulizer (Allergy Asthma Technology, Morton Grove, IL) connected to an AKITA inhalation device (Inamed, Gauting, Germany) was determined in six patients. In 17 additional patients bronchoalveolar lavage fluid was assessed before and after 14 days of inhalation with thrice-daily doses of 300 or 450 mg of glutathione. Intrathoracic deposition was 86.3 ± 1.4% of the emitted dose. Glutathione concentration in lavage 1 hour postinhalation was increased three- to fourfold and was still almost doubled 12 hours postinhalation. FEV₁ transiently dropped after inhalation but increased compared with pretreatment values after 14 days (p < 0.001). This improvement was not related to the lavage content of oxidized proteins and lipids, which did not change with treatment. These results show that, using a new inhalation device with high efficacy, glutathione treatment of the lower airways is feasible. Reversion of markers of oxidative injury may need longer treatment, higher doses, or different types of antioxidants.

Key Words: aerosol • antioxidant • bronchoalveolar lavage fluid • deposition • neutrophils

This article has been cited by other articles:

				B. Koller, M. Kappler, P. Latzin, A. Gaggar, M. Schreiner, S. Takyar, M. Kormann, M. Kabesch, D. Roos, M. Griese, et al. TLR Expression on Neutrophils at the Pulmonary Site of Infection: TLR1/TLR2-Mediated Up-Regulation of TLR5 Expression in Cystic Fibrosis Lung Disease J. Immunol., August 15, 2008; 181(4): 2753 - 2763. [Abstract] [Full Text] [PDF]

				J. Prousky The Treatment of Pulmonary Diseases and Respiratory-Related Conditions with Inhaled (Nebulized or Aerosolized) Glutathione Evid. Based Complement. Altern. Med., March 1, 2008; 5(1): 27 - 35. [Abstract] [Full Text] [PDF]

				I. Romieu, F. Castro-Giner, N. Kunzli, and J. Sunyer Air pollution, oxidative stress and dietary supplementation: a review Eur. Respir. J., January 1, 2008; 31(1): 179 - 197. [Abstract] [Full Text] [PDF]

				P. K. Vayalil, K. E. Iles, J. Choi, A.-K. Yi, E. M. Postlethwait, and R.-M. Liu Glutathione suppresses TGF-beta-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter Am J Physiol Lung Cell Mol Physiol, November 1, 2007; 293(5): L1281 - L1292. [Abstract] [Full Text] [PDF]

				C. Kariya, H. Leitner, E. Min, C. van Heeckeren, A. van Heeckeren, and B. J. Day A role for CFTR in the elevation of glutathione levels in the lung by oral glutathione administration Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1590 - L1597. [Abstract] [Full Text] [PDF]

				V. Starosta, F. Ratjen, E. Rietschel, K. Paul, and M. Griese Anti-inflammatory cytokines in cystic fibrosis lung disease Eur. Respir. J., September 1, 2006; 28(3): 581 - 587. [Abstract] [Full Text] [PDF]

				E. F. McKone, J. Shao, D. D. Frangolias, C. L. Keener, C. A. Shephard, F. M. Farin, M. R. Tonelli, P. D. Pare, A. J. Sandford, M. L. Aitken, et al. Variants in the Glutamate-Cysteine-Ligase Gene Are Associated with Cystic Fibrosis Lung Disease Am. J. Respir. Crit. Care Med., August 15, 2006; 174(4): 415 - 419. [Abstract] [Full Text] [PDF]

				H. Grasemann, F. Kurtz, and F. Ratjen Inhaled L-Arginine Improves Exhaled Nitric Oxide and Pulmonary Function in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., July 15, 2006; 174(2): 208 - 212. [Abstract] [Full Text] [PDF]

				T. J. Moraes, J. Plumb, R. Martin, E. Vachon, V. Cherepanov, A. Koh, C. Loeve, J. Jongstra-Bilen, J. H. Zurawska, J. V. Kus, et al. Abnormalities in the Pulmonary Innate Immune System in Cystic Fibrosis Am. J. Respir. Cell Mol. Biol., March 1, 2006; 34(3): 364 - 374. [Abstract] [Full Text] [PDF]

				V. Starosta, E. Rietschel, K. Paul, U. Baumann, and M. Griese Oxidative Changes of Bronchoalveolar Proteins in Cystic Fibrosis. Chest, February 1, 2006; 129(2): 431 - 437. [Abstract] [Full Text] [PDF]

				R. L. Lee, R. C. Rancourt, G. del Val, K. Pack, C. Pardee, F. J. Accurso, and C. W. White Thioredoxin and dihydrolipoic acid inhibit elastase activity in cystic fibrosis sputum Am J Physiol Lung Cell Mol Physiol, November 1, 2005; 289(5): L875 - L882. [Abstract] [Full Text] [PDF]

				A. Bush, F. Accurso, W. MacNee, S. C. Lazarus, and E. Abraham Cystic Fibrosis, Pediatrics, Control of Breathing, Pulmonary Physiology and Anatomy, and Surfactant Biology in AJRCCM in 2004 Am. J. Respir. Crit. Care Med., March 15, 2005; 171(6): 545 - 553. [Full Text] [PDF]

				B. J. Day Glutathione: A Radical Treatment for Cystic Fibrosis Lung Disease? Chest, January 1, 2005; 127(1): 12 - 14. [Full Text] [PDF]

				C. Bishop, V. M. Hudson, S. C. Hilton, and C. Wilde A Pilot Study of the Effect of Inhaled Buffered Reduced Glutathione on the Clinical Status of Patients With Cystic Fibrosis Chest, January 1, 2005; 127(1): 308 - 317. [Abstract] [Full Text] [PDF]

				A. J. Kettle, T. Chan, I. Osberg, R. Senthilmohan, A. L. P. Chapman, T. J. Mocatta, and J. S. Wagener Myeloperoxidase and Protein Oxidation in the Airways of Young Children with Cystic Fibrosis Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1317 - 1323. [Abstract] [Full Text] [PDF]